Michael Rafii on Down syndrome-related Alzheimer’s disease
People with Down syndrome face a high risk of developing Alzheimer’s disease, which is the leading cause of death in this population over the age of 35.In this episode, Morgane Boillot (Senior Editor) is joined by Professor Michael Rafii to explore the intersection of Down syndrome and Alzheimer’s disease. They discuss the latest research into disease pathology, biomarkers, and clinical trials, and examine the key challenges and future opportunities in understanding and treating Alzheimer’s disease in individuals with Down syndrome.Read the Rapid Review:https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(25)00237-6/fulltext?dgcid=buzzsprout_icw_podcast_August_25_laneurContinue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv
--------
22:41
--------
22:41
Amit Bar-Or on fenebrutinib for relapsing multiple sclerosis
In this episode, host Laura Hart chats with Professor Amit Bar-Or (University of Pennsylvania) about the potential of the BTK inhibitor fenebrutinib in treating relapsing multiple sclerosis, highlighting future challenges in MS research.Read the full article:https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(25)00174-7/fulltext?dgcid=buzzsprout_icw_podcast_July_25_laneurContinue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv
Editors at The Lancet Neurology, in conversation with the journal’s authors, explore their latest research and its impact on people’s health, healthcare, and health policy.A monthly audio companion to the journal, this podcast covers a broad range of topics, from sleep habits to amyloid biomarkers in Alzheimer’s, the diagnosis and classification of optic neuritis to treatment of Creutzfeldt-Jakob disease, and more.
Brasil